NanoString Technologies, Inc. (NSTGQ)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
NanoString Technologies, Inc. (NSTGQ) trades at $0.07 with AI Score 46/100 (Grade C). NanoString Technologies, Inc. is a biotechnology company focused on developing and commercializing genomic and proteomic analysis systems. Market cap: $3.31M, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for NSTGQ: NSTGQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates NSTGQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
NSTGQ: the 1 perspectives are evenly split.
How is this calculated? →NanoString Technologies, Inc. (NSTGQ) Healthcare & Pipeline Overview
NanoString Technologies, Inc. develops and markets systems for genomic and proteomic analysis, including the nCounter Analysis System and GeoMx Digital Spatial Profiler. The company serves the Americas, Europe, and Asia-Pacific regions. Currently undergoing Chapter 11 reorganization, it faces challenges in the competitive medical instruments and supplies sector.
What Is the Investment Thesis for NSTGQ?
NanoString Technologies, Inc. faces significant challenges following its Chapter 11 filing in February 2024. The company's future hinges on successful reorganization and continued innovation in the genomics and proteomics analysis space. Key value drivers include the continued adoption of the GeoMx DSP system and strategic collaborations to expand its technology platforms. The company's beta of 0.21 suggests low volatility relative to the market, but this may not reflect the inherent risks associated with a company undergoing bankruptcy proceedings. Investors should closely monitor the reorganization process and the company's ability to maintain its competitive edge in a rapidly evolving market. The outcome of the Chapter 11 process will significantly impact the long-term viability of NanoString.
Based on FMP financials and quantitative analysis
NSTGQ Key Highlights
- NanoString Technologies, Inc. filed for Chapter 11 reorganization on February 4, 2024, impacting its financial stability.
- The company's nCounter Analysis System is a key product, offering automated multi-application digital detection and counting.
- Development of the GeoMx DSP system represents a strategic focus on spatial biology.
- Collaborations with Lam Research and the Parker Institute for Cancer Immunotherapy aim to expand technology platforms and therapeutic applications.
- The company's beta of 0.21 indicates lower volatility compared to the overall market, but this may not reflect the risks associated with Chapter 11.
Who Are NSTGQ's Competitors?
NSTGQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| NYXH Nyxoah S.A. | $1.75 | +1.74% | $69.31M | 69 |
| KMTS Kestra Medical Technologies, Ltd. | $27.70 | +2.67% | $1.62B | 67 |
| ZTEK Zentek Ltd. | $0.46 | +2.88% | $49.90M | 63 |
| OMIC Singular Genomics Systems, Inc. | $20.01 | +0.00% | $50.77M | 61 |
| BLMHF Bloom Health Partners Inc. | $0.11 | +0.00% | $5.22M | 51 |
| FSPKF Fisher & Paykel Healthcare Corporation Limited | $22.52 | +0.00% | $13.23B | 51 |
| CZMWY Carl Zeiss Meditec AG | $32.76 | +3.56% | $2.87B | 51 |
| STAA STAAR Surgical Company | $27.45 | -1.21% | $1.37B | 51 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NSTGQ's Key Strengths?
- Innovative nCounter technology for digital detection and counting.
- Development of GeoMx DSP system for spatial biology.
- Strategic collaborations with research institutions and companies.
- Established customer base in genomics and proteomics research.
What Are NSTGQ's Weaknesses?
- Chapter 11 reorganization impacting financial stability.
- Dependence on a limited number of key products.
- Intense competition in the medical instruments and supplies industry.
- OTC market trading increases volatility and reduces liquidity.
What Could Drive NSTGQ Stock Higher?
- Progress in Chapter 11 reorganization proceedings, including court approvals and restructuring milestones.
- Potential for new strategic partnerships or collaborations to enhance technology platforms.
- Development and launch of new assays and applications for the nCounter and GeoMx DSP systems.
- Continued adoption and utilization of the GeoMx DSP system in spatial biology research.
- Publication of research studies utilizing NanoString's technologies, validating their utility and driving adoption.
What Are the Key Risks for NSTGQ?
- Uncertainty surrounding the Chapter 11 reorganization process and potential outcomes.
- Loss of key personnel or customers due to financial instability.
- Technological obsolescence and competition from new entrants in the genomics and proteomics market.
- Regulatory changes impacting the development and commercialization of diagnostic and research tools.
- Limited liquidity and higher volatility associated with trading on the OTC market.
What Are the Growth Opportunities for NSTGQ?
- Expansion of GeoMx DSP System: The GeoMx Digital Spatial Profiler (DSP) system offers significant growth potential by enabling spatial biology research. This technology allows researchers to analyze the spatial distribution of proteins and RNA within tissue samples, providing valuable insights into disease mechanisms and treatment responses. The spatial biology market is expected to grow as researchers increasingly recognize the importance of understanding cellular interactions within their native microenvironments. Successful commercialization and adoption of the GeoMx DSP system could drive substantial revenue growth for NanoString, provided the company can navigate its current financial challenges.
- Strategic Collaborations: NanoString's collaborations, such as those with Lam Research and the Parker Institute for Cancer Immunotherapy, present opportunities for technology development and market expansion. Collaborating with Lam Research for NGS sequencing platform development could enhance NanoString's capabilities in genomic analysis. The partnership with the Parker Institute for Cancer Immunotherapy aims to develop CAR-T regimens, potentially leading to new therapeutic applications and revenue streams. These collaborations can leverage external expertise and resources to accelerate innovation and broaden NanoString's market reach.
- Increased Adoption of nCounter Systems: The nCounter Analysis System remains a core product for NanoString, offering automated multi-application digital detection and counting. Expanding the installed base of nCounter systems and increasing utilization rates among existing customers can drive revenue growth. This can be achieved through targeted marketing efforts, new application development, and enhanced customer support. The nCounter platform's versatility and ease of use make it a noteworthy option for researchers in various fields, including oncology, immunology, and drug discovery.
- Expansion into New Geographic Markets: NanoString currently serves the Americas, Europe, the Middle East, and the Asia Pacific regions. Expanding into new geographic markets, particularly in emerging economies, could unlock additional growth opportunities. This would require establishing distribution networks, adapting products to local market needs, and navigating regulatory requirements. Successful geographic expansion can diversify NanoString's revenue base and reduce its reliance on existing markets.
- Development of New Assays and Applications: NanoString can drive growth by developing new assays and applications for its existing platforms. This includes expanding its portfolio of CodeSets and panels for oncology, immunology, infectious disease, and neuroscience applications. By continuously innovating and offering new tools for researchers, NanoString can attract new customers and increase the value of its existing platforms. This requires ongoing investment in research and development and a deep understanding of customer needs.
What Opportunities Does NSTGQ Have?
- Expansion of GeoMx DSP system into new markets.
- Development of new assays and applications for existing platforms.
- Increased adoption of nCounter systems in emerging economies.
- Leveraging collaborations for technology development and market expansion.
What Threats Does NSTGQ Face?
- Prolonged Chapter 11 proceedings and potential liquidation.
- Technological obsolescence and competition from new entrants.
- Regulatory changes impacting diagnostic and research tools.
- Economic downturn affecting research funding and customer spending.
What Are NSTGQ's Competitive Advantages?
- Proprietary nCounter technology for digital detection and counting.
- Established customer base in the genomics and proteomics research community.
- Strategic collaborations with leading research institutions and companies.
- Development of innovative spatial biology solutions with the GeoMx DSP system.
What Does NSTGQ Do?
NanoString Technologies, Inc., founded in 2003 and headquartered in Seattle, Washington, develops, manufactures, and sells technologies for scientific and clinical information in genomics and proteomics. The company's flagship product is the nCounter Analysis System, an automated platform for multi-application digital detection and counting. This system includes the nCounter Pro and FLEX systems, which utilize the Prep Station for sample preparation and the nCounter Digital Analyzer for data collection. NanoString also offers the nCounter SPRINT Profiler, which integrates liquid handling and digital analysis via a microfluidic cartridge. Complementing its hardware, NanoString provides the nSolver Analysis Software for data normalization and analysis. The company's product portfolio extends to custom CodeSets and panels for oncology, immunology, infectious disease, and neuroscience applications. Additionally, NanoString offers Master Kits, cartridges, and reagents to support instrument operation, as well as Prosigna in vitro diagnostic kits. The company is actively developing the GeoMx DSP system to advance spatial biology research. NanoString collaborates with Lam Research Corporation for NGS sequencing platform development and with the Parker Institute for Cancer Immunotherapy to enhance CAR-T regimens. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
What Products and Services Does NSTGQ Offer?
- Develops and manufactures technology for scientific and clinical information.
- Offers the nCounter Analysis System for automated digital detection and counting.
- Provides nCounter Pro and FLEX systems for sample preparation and data collection.
- Offers nCounter SPRINT Profiler for liquid handling and digital analysis.
- Provides nSolver Analysis Software for data analysis and normalization.
- Offers custom CodeSets and panels for oncology, immunology, and neuroscience applications.
- Develops the GeoMx DSP system for spatial biology.
How Does NSTGQ Make Money?
- Sells nCounter Analysis Systems and related instruments.
- Generates revenue from the sale of CodeSets, panels, and reagents.
- Provides software licenses for nSolver Analysis Software.
- Forms strategic collaborations for technology development and market expansion.
What Industry Does NSTGQ Operate In?
NanoString Technologies, Inc. operates within the medical instruments and supplies industry, a sector characterized by technological innovation and increasing demand for advanced diagnostic and research tools. The market is driven by advancements in genomics and proteomics, personalized medicine, and the growing need for efficient and accurate analysis systems. Competitors include companies like ATIP (ATI Physical Therapy, Inc.), DLTNF (Deltronics AB), EEVVF (Elekta AB), FTHWF (Faron Pharmaceuticals Oy), and GABLF (G Medical Innovations Holdings Ltd.). NanoString's focus on spatial biology with its GeoMx DSP system positions it to capitalize on emerging trends in the field.
Who Are NSTGQ's Key Customers?
- Academic research institutions
- Pharmaceutical and biotechnology companies
- Clinical research organizations
- Government research agencies
NanoString Technologies, Inc. (NSTGQ) Valuation Context
Valued at $3.31M, NSTGQ is classified as a micro-cap stock. Relative to its peer group, NSTGQ's quantitative score of 46/100 is below the peer average of 62/100.
Key Financial Metrics
Return on assets is -45.1%, showing how much profit it generates from its asset base. A current ratio of 4.87 indicates the company holds enough short-term assets to cover its near-term obligations.
NSTGQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Innovative nCounter technology for digital detection and counting.
- Development of GeoMx DSP system for spatial biology.
- Strategic collaborations with research institutions and companies.
- Established customer base in genomics and proteomics research.
Bear Case
- Chapter 11 reorganization impacting financial stability.
- Dependence on a limited number of key products.
- Intense competition in the medical instruments and supplies industry.
- OTC market trading increases volatility and reduces liquidity.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
NSTGQ Latest News
No recent news available for NSTGQ.
NSTGQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NSTGQ.
Price Targets
Wall Street price target analysis for NSTGQ.
NSTGQ MoonshotScore
What does this score mean?
The MoonshotScore rates NSTGQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Mark A. Winham
CEO
Mark A. Winham is the Chief Executive Officer of NanoString Technologies, Inc. His background includes extensive experience in managing and leading organizations, particularly in the context of technology and healthcare. He is responsible for overseeing the company's strategic direction, managing its operations, and ensuring its financial stability. His leadership is critical during the company's Chapter 11 reorganization process.
Track Record: Under Mark A. Winham's leadership, NanoString Technologies, Inc. has focused on advancing its spatial biology capabilities with the GeoMx DSP system and maintaining its core nCounter business. His tenure has been marked by efforts to navigate the challenges of a competitive market and the complexities of Chapter 11 proceedings. Key decisions include strategic collaborations and efforts to streamline operations.
NSTGQ OTC Market Information
The OTC Other tier represents the lowest tier of the over-the-counter (OTC) market, indicating that NanoString Technologies, Inc. does not meet the listing requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, be undergoing financial distress (as in NanoString's case with its Chapter 11 filing), or have chosen not to comply with the stricter standards of the higher tiers. Unlike NYSE or NASDAQ listings, OTC Other stocks often lack the same level of regulatory oversight and transparency, leading to increased risk for investors.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure and transparency.
- Higher price volatility due to lower trading volume.
- Potential for wider bid-ask spreads, increasing transaction costs.
- Risk of delisting and further decline in value.
- Uncertainty surrounding the Chapter 11 reorganization process.
- Review the company's Chapter 11 filings and reorganization plan.
- Assess the company's ability to continue operations during bankruptcy.
- Evaluate the potential for recovery and future growth.
- Monitor news and developments related to the company's financial situation.
- Consult with a financial advisor to understand the risks involved.
- Verify the company's disclosure status and available financial reports.
- Established history as a developer of genomic and proteomic analysis systems.
- Existing customer base in academic and pharmaceutical research.
- Ongoing development of innovative technologies like the GeoMx DSP system.
- Strategic collaborations with research institutions and companies.
NanoString Technologies, Inc. Healthcare Stock: Key Questions Answered
What does NanoString Technologies, Inc. do?
NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information, primarily in the fields of genomics and proteomics. Their main product is the nCounter Analysis System, which automates the detection and counting of multiple molecules in a biological sample. The company also develops the GeoMx Digital Spatial Profiler (DSP) system, which enables spatial biology research. NanoString serves academic, pharmaceutical, and clinical research markets across the Americas, Europe, and Asia-Pacific. Currently, the company is undergoing Chapter 11 reorganization.
What do analysts say about NSTGQ stock?
As of March 16, 2026, formal analyst coverage of NSTGQ is limited due to the company's Chapter 11 reorganization and OTC market listing. Investors should conduct their own due diligence and consider the risks associated with the company's financial situation. Key valuation metrics are difficult to assess given the uncertainty surrounding the reorganization process. Growth considerations depend on the company's ability to successfully restructure and continue innovating in the genomics and proteomics space.
What are the main risks for NSTGQ?
The primary risk for NanoString Technologies, Inc. is the uncertainty surrounding its Chapter 11 reorganization. This includes the potential for liquidation, dilution of existing shareholders, and delays in restructuring. Additional risks include technological obsolescence, competition from other companies in the genomics and proteomics market, and regulatory changes impacting diagnostic and research tools. Trading on the OTC market also presents risks related to liquidity and price volatility. Investors should carefully consider these risks before investing in NSTGQ.
What are the key factors to evaluate for NSTGQ?
NanoString Technologies, Inc. (NSTGQ) holds an AI score of 46/100 (low). Not financial advice.
How frequently does NSTGQ data refresh on this page?
NSTGQ prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven NSTGQ's recent stock price performance?
NanoString Technologies, Inc. (NSTGQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative nCounter technology for digital detection and counting. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NSTGQ overvalued or undervalued right now?
Valuing NanoString Technologies, Inc. (NSTGQ) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying NSTGQ?
Before investing in NanoString Technologies, Inc. (NSTGQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- The company is currently undergoing Chapter 11 reorganization, which introduces significant uncertainty.